Parkinson's

AC Immune SA (NASDAQ:ACIU) revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease. Dr. Andrea Pfeifer, CEO of AC Immune, commented: “The level of immunogenicity after only 3 months of...

On Tuesday, MeiraGTx Holdings plc (NASDAQ:MGTX) released topline data from its clinical bridging study of AAV-GAD for Parkinson’s disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx...

On Monday, Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look forward to strengthening our relationship with Sanofi as the VTX3232 clinical programs progress, with data from the Phase 2a trial in patients with early...

In response to recent conjecture, the White House has confirmed that U.S. President Joe Biden is not undergoing treatment for Parkinson’s disease. What Happened: The statement was made following a New York Times disclosure that a Parkinson’s specialist had been to the White House eight...

On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel narrowly recommended approval for the company's gene therapy for Duchenne Muscular Dystrophy (DMD)....

A San Francisco-based software company received permission from the U.S. Food and Drug Administration to use Apple Inc. (NASDAQ: AAPL) wearable technology to track Parkinson's symptoms. Rune Labs' StrivePD software "draws data directly from Apple's Movement Disorder API, which...

Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation. “We are pleased that the FDA has granted Fast Track Designation for PR001, which...

Smaller gene therapy biotechs are taking the spotlight given the M&A interest surrounding them. One such gene therapy company saw its shares rallying by more than 30 percent Monday following the release of clinical trial results for two of its gene therapies. What Happened...

Voyager Therapeutics Inc (NASDAQ: VYGR) faded this week on news of a CEO transition, but the firm caught a boost Friday from a new advocate. The Rating Morgan Stanley analyst Matthew Harrison initiated coverage of Voyager with an Overweight rating and $36 price target. The Thesis The...

A Morgan Stanley analyst predicts near-term upside for the shares of Denali Therapeutics Inc. (NASDAQ: DNLI), thanks to its work in neuroscience and particularly its lead programs in Parkinson's and Alzheimer's. The Analyst Morgan Stanley analyst Matthew Harrison initiated coverage of...